COMPANY WORKBOOK · RXRX
Recursion Pharmaceuticals, Inc.
Healthcare & Life Sciences · Biotechnology
$3.97+3.66%
49/100
INTERACTIVE PRICE CHART
Trend and moving averages
RELATIVE PERFORMANCE
RXRX versus SPY and SMH
Indexed to 100
Cross-sectional ranking
Scores are percentile-ranked against the current Young Bull universe and stored by date in PostgreSQL.
Healthcare & Life Sciences
This company is available as a market-data workbook. Young Bull has not added a manual investment thesis for it yet.
MODEL READ
Overall score: 48.8. Last ranked 2026-09-22.
QUARTERLY FUNDAMENTALS
Revenue and earnings power
TRAILING P/EN/A
PRICE / SALES39.59
EV / EBITDA-3.58
BOOK VALUEN/A
GROSS MARGIN0.0%
PROFIT MARGIN0.0%
RETURN ON EQUITY-56.6%
FREE CASH FLOW-219.49M
What it does
Recursion Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in the decoding biology and chemistry by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery in the United States and the United Kingdom. The company develops REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-617, which is in Phase 1/2 clinical trial to treat advanced solid tumors; REC-1245, which is in Phase 1/2 clinical trial to treat biomarker-enriched solid tumors and lymphoma; REC-3565 that is in Phase 1/2 for the treatment of relapsed or refractory B-cell malignancies; and REC-4539, a reversible, CNS penetrant, orally bioavailable, and potential best-in-class inhibitor of LSD1 for the treatment of solid tumors and hematology oncology. Its preclinical stage product includes REC-7735 for the treatment of HR+ breast cancer; and REC-102 for the treatment of hypophosphatasia. The company has collaboration and agreement with Roche & Genentech; Sanofi; Bayer AG; Tempus; and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Salt Lake City, Utah.
PRIMARY SOURCES